KR20200072445A - 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제 - Google Patents

암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제 Download PDF

Info

Publication number
KR20200072445A
KR20200072445A KR1020197031888A KR20197031888A KR20200072445A KR 20200072445 A KR20200072445 A KR 20200072445A KR 1020197031888 A KR1020197031888 A KR 1020197031888A KR 20197031888 A KR20197031888 A KR 20197031888A KR 20200072445 A KR20200072445 A KR 20200072445A
Authority
KR
South Korea
Prior art keywords
bad
agent
expression
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197031888A
Other languages
English (en)
Korean (ko)
Inventor
앵거스 달글리쉬
웨이 루이
Original Assignee
엘디엔 파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1704910.7A external-priority patent/GB201704910D0/en
Priority claimed from GBGB1718806.1A external-priority patent/GB201718806D0/en
Application filed by 엘디엔 파마 리미티드 filed Critical 엘디엔 파마 리미티드
Priority to KR1020247026962A priority Critical patent/KR20240125082A/ko
Publication of KR20200072445A publication Critical patent/KR20200072445A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197031888A 2017-03-28 2018-03-28 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제 Ceased KR20200072445A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247026962A KR20240125082A (ko) 2017-03-28 2018-03-28 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 성분

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1704910.7 2017-03-28
GBGB1704910.7A GB201704910D0 (en) 2017-03-28 2017-03-28 High dose combi I
GB1718806.1 2017-11-14
GBGB1718806.1A GB201718806D0 (en) 2017-11-14 2017-11-14 Breast cancer treatment
PCT/GB2018/050843 WO2018178690A1 (en) 2017-03-28 2018-03-28 An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247026962A Division KR20240125082A (ko) 2017-03-28 2018-03-28 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 성분

Publications (1)

Publication Number Publication Date
KR20200072445A true KR20200072445A (ko) 2020-06-22

Family

ID=61952738

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197031888A Ceased KR20200072445A (ko) 2017-03-28 2018-03-28 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제
KR1020247026962A Pending KR20240125082A (ko) 2017-03-28 2018-03-28 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 성분

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247026962A Pending KR20240125082A (ko) 2017-03-28 2018-03-28 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 성분

Country Status (8)

Country Link
EP (1) EP3600433B1 (https=)
JP (2) JP7657590B2 (https=)
KR (2) KR20200072445A (https=)
CN (1) CN111050801B (https=)
AU (1) AU2018244806B2 (https=)
CA (1) CA3083850A1 (https=)
ES (1) ES2897790T3 (https=)
WO (1) WO2018178690A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049375A1 (en) 2000-03-15 2001-12-06 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US20030144312A1 (en) 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
SMT202500474T1 (it) * 2010-12-03 2026-01-12 Nalpropion Pharmaceuticals Llc Aumento della biodisponibilità farmacologica nella terapia con naltrexone
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression

Also Published As

Publication number Publication date
KR20240125082A (ko) 2024-08-19
CN111050801B (zh) 2023-03-28
CN111050801A (zh) 2020-04-21
ES2897790T3 (es) 2022-03-02
EP3600433A1 (en) 2020-02-05
AU2018244806A1 (en) 2019-11-21
CA3083850A1 (en) 2019-10-04
JP2025027084A (ja) 2025-02-26
JP7657590B2 (ja) 2025-04-07
JP2020515649A (ja) 2020-05-28
US20200101066A1 (en) 2020-04-02
EP3600433B1 (en) 2021-05-05
AU2018244806B2 (en) 2023-12-21
WO2018178690A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
KR102615210B1 (ko) 난소암의 치료에 사용되는 티노스타무스틴
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
JP2022524885A (ja) ナルトレキソン及びカンナビノイドを含む癌の治療
WO2016145298A1 (en) METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
Guan et al. Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
US11351165B2 (en) Agent that increases the expression of the opioid kappa 1 for the treatment of cancer
JP2021505571A (ja) 末梢ｔ細胞リンパ腫および皮膚ｔ細胞リンパ腫を治療するための組成物および方法
SG194047A1 (en) Combinations of akt and mek inhibitor compounds, and methods of use
AU2010224108A1 (en) Treatment of pancreatic cancer
TW201722422A (zh) 用於治療癌症之合理組合療法
KR20150042590A (ko) K-Ras 과발현된 암 세포의 이동 및 침윤 억제
JP7361779B2 (ja) がんに治療的処置をするためのｃ－１９ステロイドの組み合わせ
AU2009271406A1 (en) Methods for determining sensitivity to aminoflavones
JP7282072B2 (ja) 肺がんの治療に使用するための組み合わせ
US12611405B2 (en) Agent that increases the expression of the BCL2-associated agonist of cell death for the treatment of cancer
EP3600433B1 (en) An agent that increases the expresssion of the bcl2-associated agonist of cell death for the treatment of cancer
CN112218627B (zh) 前药及其在医学上的应用
CA3147658A1 (en) Small molecule liver x receptor modulators and uses thereof
Cui et al. Disulfiram alone regulates the radiosensitivity of lung cancer through NF-κB pathway and regulates the immune microenvironment after radiotherapy by targeting PD-L1 through c-Myc
Lee et al. 368 Demonstration of broad in vivo anti-tumor activity of ARRY-142886 (AZD-6244), a potent and selective MEK inhibitor
Caiazza et al. 527 ADAM17 as a Therapeutic Target for the Treatment of Breast Cancer: Preclinical Studies with an Inhibitory Monoclonal Antibody
Cook Therapeutic and chemopreventive potential of luteolin against growth and metastasis of breast cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000